Blockade of telomerase reverse transcriptase enhances chemosensitivity in head and neck cancers through inhibition of AKT/ ERK signaling pathways

Oncotarget

Volumn 6, Issue 34, 2015, Pages 35908-35921

  Zhao, Tengda ^a,b   Hu, Fengchun ^a,c   Liu, Xingguang ^a   Tao, Qian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

AKT; Chemosensitivity; ERK; HNSCC; TERT

Indexed keywords

CASPASE 3; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; SHORT HAIRPIN RNA; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMORTALIZED CELL LINE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INDUCTION CHEMOTHERAPY; KERATINOCYTE; MAJOR CLINICAL STUDY; MITOCHONDRION; MOUSE; NONHUMAN; PROGNOSIS; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR INVASION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL TRANSFORMATION; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETICS; HEAD AND NECK NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ADULT; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946840791     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5468     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61:69-90.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: a cancer journal for clinicians. 2011; 61:212-236.
3. Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. The Lancet Oncology. 2013; 14:257-264.
4. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer cell. 2004; 5:311-316.
5. Liu JP, Chen SM, Cong YS, Nicholls C, Zhou SF, Tao ZZ, Li H. Regulation of telomerase activity by apparently opposing elements. Ageing Res Rev. 2010; 9:245-256.
6. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, Popescu NC, Weinberg RA. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A. 2002; 99:12606-12611.
7. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol. 2003; 5:474-479.
8. Yang C, Przyborski S, Cooke MJ, Zhang X, Stewart R, Anyfantis G, Atkinson SP, Saretzki G, Armstrong L, Lako M. A key role for telomerase reverse transcriptase unit in modulating human embryonic stem cell proliferation, cell cycle dynamics, and in vitro differentiation. Stem Cells. 2008; 26:850-863.
9. Lee J, Sung YH, Cheong C, Choi YS, Jeon HK, Sun W, Hahn WC, Ishikawa F, Lee HW. TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene. 2008; 27:3754-3760.
10. Shay JW, Wright WE. Hallmarks of telomeres in ageing research. The Journal of pathology. 2007; 211:114-123.
11. Kapanadze B, Morris E, Smith E, Trojanowska M. Establishment and characterization of scleroderma fibroblast clonal cell lines by introduction of the hTERT gene. J Cell Mol Med. 2010; 14:1156-1165.
12. Wieser M, Stadler G, Jennings P, Streubel B, Pfaller W, Ambros P, Riedl C, Katinger H, Grillari J, Grillari-Voglauer R. hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am J Physiol-Renal. 2008; 295:F1365-F1375.
13. Bertorelle R, Briarava M, Rampazzo E, Biasini L, Agostini M, Maretto I, Lonardi S, Friso ML, Mescoli C, Zagonel V, Nitti D, De Rossi A, Pucciarelli S. Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. British Journal of Cancer. 2013; 108:278-284.
14. Eid MM, Helmy NA, Omar IM, Mohamed AA, El Sewefy D, Fadel IM, Helal RA. Clinical significance of telomerase genes (hTERC and hTERT) amplification in patients with acute myeloid leukemia. Gulf J Oncolog. 2013; 1:51-60.
15. Lotsch D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, Webersinke G, Pichler J, Berger W, Spiegl-Kreinecker S. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro-oncology. 2013; 15:423-432.
16. Nakashima A, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Ohge H, Oda M, Sueda T, Hiyama E. Usefulness of Human Telomerase Reverse Transcriptase in Pancreatic Juice as a Biomarker of Pancreatic Malignancy. Pancreas. 2009; 38:527-533.
17. Indran IR, Hande MP, Pervaiz S. hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. Cancer Res. 2011; 71:266-276.
18. Sahin E, DePinho RA. Axis of ageing: telomeres, p53 and mitochondria. Nature reviews Molecular cell biology. 2012; 13:397-404.
19. Yang X, Fraser M, Moll UM, Basak A, Tsang BK. Aktmediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 2006; 66:3126-3136.
20. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339:959-961.
21. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997; 33:787-791.
22. Dashzeveg N, Yoshida K. Cell death decision by p53 via control of the mitochondrial membrane. Cancer letters. 2015;.
23. Zhao T, Hu F, Qiao B, Chen Z, Tao Q. Telomerase reverse transcriptase potentially promotes the progression of oral squamous cell carcinoma through induction of epithelialmesenchymal transition. International journal of oncology. 2015; 46:2205-2215.
24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
25. Chen CS, Ho DR, Chen FY, Chen CR, Ke YD, Su JG. AKT mediates actinomycin D-induced p53 expression. Oncotarget. 2014; 5:693-703.
26. Hamilton G, Abraham AG, Morton J, Sampson O, Pefani DE, Khoronenkova S, Grawenda A, Papaspyropoulos A, Jamieson N, McKay C, Sansom O, Dianov GL, O'Neill E. AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget. 2014; 5:6142-6167.
27. Bhardwaj V, Noto JM, Wei J, Andl C, El-Rifai W, Peek RM, Zaika AI. Helicobacter pylori bacteria alter the p53 stress response via ERK-HDM2 pathway. Oncotarget. 2015; 6:1531-1543.
28. Bertorelle R, Briarava M, Rampazzo E, Biasini L, Agostini M, Maretto I, Lonardi S, Friso ML, Mescoli C, Zagonel V, Nitti D, De Rossi A, Pucciarelli S. Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. Br J Cancer. 2013; 108:278-284.
29. Pelosi G, Schianchi E, Dell'Orto P, Veronesi G, Spaggiari L, Pasini F, Sozzi G, Brambilla E, Griso C, Viale G. Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients. Virchows Arch. 2006; 448:7-15.
30. Gigek CO, Leal MF, Silva PN, Lisboa LC, Lima EM, Calcagno DQ, Assumpcao PP, Burbano RR, Smith Mde A. hTERT methylation and expression in gastric cancer. Biomarkers. 2009; 14:630-636.
31. Saini N, Srinivasan R, Chawla Y, Sharma S, Chakraborti A, Rajwanshi A. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status. Liver Int. 2009; 29:1162-1170.
32. Divella R, Tommasi S, Lacalamita R, Daniele A, Abbate I, Garrisi VM, Savino E, Coviello M, Rubini V, Simone G, Paradiso A, Quaranta M. Circulating hTERT DNA in early breast cancer. Anticancer Res. 2009; 29:2845-2849.
33. Yang K, Fu LW. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review. Critical reviews in oncology/hematology. 2015; 93:277-292.
34. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, Karnezis AN, Attardi LD. Distinct p53 transcriptional programs dictate acute DNAdamage responses and tumor suppression. Cell. 2011; 145:571-583.
35. Yao Y, Bellon M, Shelton SN, Nicot C. Tumor suppressors p53, p63TAalpha, p63TAy, p73alpha, and p73beta use distinct pathways to repress telomerase expression. J Biol Chem. 2012; 287:20737-20747.
36. Gritsina G, Xiao F, O'Brien SW, Gabbasov R, Maglaty MA, Xu RH, Thapa RJ, Zhou Y, Nicolas E, Litwin S, Balachandran S, Sigal LJ, Huszar D, Connolly DC. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth. Molecular cancer therapeutics. 2015; 14:1035-1047.
37. Wang ZY, Martin D, Molinolo AA, Patel V, IglesiasBartolome R, Degese MS, Vitale-Cross L, Chen QM, Gutkind JS. mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations. Jnci-J Natl Cancer I. 2014; 106.
38. Buonato JM, Lazzara MJ. ERK1/2 Blockade Prevents Epithelial-Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition. Cancer Res. 2014; 74:309-319.
39. Hoffmeyer K RA, Rudloff S, Anton R, Hierholzer A, Del Valle I, Hein K, Vogt R, Kemler R. Wntβ-catenin signaling regulates telomerase in stem cells and cancer cells. Science. 2012; 336:6.